Heart failure with preserved ejection fraction (HFpEF) remains a medical anomaly that baffles researchers and physicians alike. The overall phenotypical changes of diastolic function and left ventricular hypertrophy observed in HFpEF are definable; however, the metabolic and molecular alterations that ultimately produce these changes are not well established. Comorbidities such as obesity, hypertension, and diabetes, as well as general aging, play crucial roles in its development and progression. Various animal models have recently been developed to better understand the pathophysiological and metabolic developments in HFpEF and to illuminate novel avenues for pharmacotherapy. These models include multi‐hit rodents and feline aortic constriction animals. Recently, genomic, proteomic, and metabolomic approaches have been used to define altered signaling pathways in the heart associated with HFpEF, including those involved in inflammation, cGMP‐related, Ca 2+ handling, mitochondrial respiration, and the unfolded protein response in endoplasmic reticulum stress. This article aims to present an overview of what has been learnt by these studies, focusing mainly on the findings in common while highlighting unresolved issues. The knowledge gained from these research models will not simply be of benefit for treating HFpEF but will undoubtedly provide new insights into the mechanisms by which the heart deals with external stresses and how the processes involved can fail.
4 March 2025 in Journal of the American Heart Association
Background: Cardiorenal syndrome type 1 is characterized by the development of acute kidney injury following acute cardiac illness and notably acute myocardial infarction (MI). Acute kidney injury is considered an independent risk factor that increases mortality rate substantially. Nicotinamide adenine dinucleotide (NAD) is an important coenzyme in energy metabolism and oxidative phosphorylation, and in its oxidized form it is a substrate for multiple NAD + ‐dependent enzymes such as sirtuins and poly‐ADP ribose polymerases. Decreased cardiac NAD levels, along with a downregulation of NAMPT (nicotinamide phosphoribosyl transferase), have been reported following MI. A compensatory upregulation in NMRK (nicotinamide riboside kinase) 2, an NAD + biosynthetic enzyme that uses nicotinamide riboside (NR) to generate NAD + , takes place in the heart after MI, but the impact on kidney NAD metabolism and function has not been addressed before. Methods and Results: MI was induced by ligating the left anterior descending coronary artery in 2‐month‐old C57BL6/J mice, followed by the administration of NR (IP injection, 400 mg/kg per day) for 4 and 7 days. We hypothesized that NR treatment could be a potentially promising therapy for MI‐induced acute kidney injury. Our findings showed no significant improvement in cardiac ejection fraction following NR treatment at days 4 and 7 post‐MI, whereas kidney functions were enhanced and morphological alterations and cell death decreased. The observed renal protection seems to be mediated by an upregulation of NAMPT‐mediated increase in renal NAD levels, notably in the distal tubules. Conclusions: Our findings indicate that NR could potentially be a promising therapy for acute kidney injury following an early stage of MI.
Problem: Strong evidence suggests that the immune system plays a critical role in the progression and development of endometriosis. This study aims at assessing the endometrial immune profile in patients with endometriosis-associated recurrent implantation failures (RIFs) following in-vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI), in comparison to women with male infertility-associated RIFs. Method of Study: This case-control study compared the endometrial immune profile in women with endometriosis-associated RIFs (case group) versus those with male infertility-associated RIFs (control group). The profile was evaluated using the ratio of IL-18/TWEAK mRNA expression levels (a biomarker for angiogenesis and Th1/Th2 balance), the ratio of IL-15/Fn14 mRNA expression levels (a biomarker for uNK cell activation/maturation), uNK cell counts, and CD56 mRNA expression levels (a marker for uNK cell mobilization). Results: The distribution of immune profiles significantly differed between the case group and the control group. The case group had fewer patients with a regulated profile (18.9% vs. 24.3%, P value 0.01) and more patients with under-activated profiles (34.2% vs. 28.4%, P value < 0.0001). Additionally, the case group had a higher proportion of immature uNK cells (46.2% vs. 39.2%, P value 0.007). The immaturity of uNK cells in endometriosis-associated RIFs appeared to be mediated by decreased IL-15 expression levels. Conclusions: The study highlights unique immune characteristics in the endometrial environment of women with endometriosis-associated RIFs, emphasizing the role of immune dysregulation in the development and progression of endometriosis.
Background: Cardiorenal syndrome (CRS) type 1 is characterized by the development of acute kidney injury (AKI) following acute cardiac illness and notably acute myocardial infarction (MI). AKI is considered an independent risk factor increasing mortality rate substantially. Nicotinamide dinucleotide (NAD) is an important coenzyme in energy metabolism and oxidative phosphorylation and in its oxidized form, a substrate for multiple NAD + -dependent enzymes such as Sirtuins and poly-ADP ribose polymerases. Decreased cardiac NAD levels along with a down-regulation of the nicotinamide phosphoribosyl transferase (NAMPT) have been reported following MI. A compensatory upregulation in nicotinamide riboside kinase (NMRK) 2, an NAD + biosynthetic enzyme that uses nicotinamide riboside (NR) to generate NAD + takes place in the heart after MI but the impact on kidney NAD metabolism and function has not been addressed before. Methods: MI was induced by ligating the left anterior descending coronary artery in 2 months old C57BL6/J mice, followed by the administration of NR (IP injection, 400mg/kg/day) for four and seven days. We hypothesized that NR treatment could be a potential promising therapy for MI-induced AKI. Results: Our findings showed no significant improvement in cardiac ejection fraction following NR treatment at days 4 and 7 post-MI, whereas kidney functions were enhanced and morphological alterations and cell death decreased. The observed renal protection seems to be mediated by an up-regulation of NAMPT-mediated increase in renal NAD levels, notably in distal tubules. Conclusion: Our findings indicate that NR could be a potential promising therapy for AKI following an early stage of MI.
Modélisation du syndrome cardiorénal de type 1 chez la souris : Etude des facteurs de risque et développement d'une approche thérapeutique basée sur la stimulation de la signalisation du NAD: L'infarctus aigu du myocarde (IM) est la principale cause de décès dans le monde. Plus de 20 % des patients hospitalisés avec un IM développent une insuffisance rénale aiguë (IRA), également connue sous le nom de syndrome cardiorénal de type I. Il a été démontré que plusieurs facteurs de risque sont impliqués dans l'exacerbation du SCR, notamment le tabagisme et le sexe masculin, entre autres. Les options thérapeutiques sont néanmoins limitées pour le traitement du SRC de type 1. Ces dernières années, plusieurs études ont mis en évidence les bénéfices d'une supplémentation en vitamine B3 pour activer la signalisation du nicotinamide adénine dinucléotide (NAD) dans différentes pathologies mais pas encore dans des modèles de SRC de type 1. L'objectif de ma thèse était de caractériser un modèle de SCR de type I chez la souris et d'évaluer l'impact de a suppression des hormones sexuelles féminines par l'ovariectomie et les effets du nicotinamide riboside (NR) en tant que thérapie prometteuse potentielle pour l'IRA suivant un IM expérimental. Nous avons constaté que l'ovariectomie aggrave les lésions rénales et l'inflammation à la suite d'un infarctus du myocarde et avons observé différentes perturbations dans la biosynthèse et la signalisation du NAD dans ce modèle. L'injection de NR n'améliore pas directement l'hémodynamique cardiaque dans la semaine suivant l'IM, mais fourni une protection robuste contre les lésions rénales, suggérant des mécanismes rénoprotecteurs directs médiés par la signalisation NAD. Ces résultats apportent une nouvelle compréhension de la pathogenèse du SRC de type 1 et ouvrent de nouvelles perspectives cliniques pour le traitement de l'IRA dans ce contexte.